Drug Profile
Fosgemcitabine palabenamide - Cardiff University/NuCana Biomed
Alternative Names: Acelarin®; CPF-31; Gemcitabine analog - Nucana; Gemcitabine-phosphoramidate; Gemcitabine-ProTide; MTL-007; NUC 1031Latest Information Update: 11 Apr 2022
Price :
$50
*
At a glance
- Originator Cardiff University
- Developer Imperial College of Science, Technology and Medicine; NuCana
- Class Antineoplastics; Pyrimidine nucleosides
- Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Ribonucleotide reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Biliary cancer; Pancreatic cancer
- Phase II Ovarian cancer
- Phase I/II Solid tumours
- No development reported Bladder cancer; Non-small cell lung cancer
Most Recent Events
- 02 Mar 2022 NuCana terminates the phase-III NuTide:121 trial in Biliary cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) Hungary, Spain, France, Czech Republic, Germany, Canada, Australia, South Korea, Taiwan, Turkey, Ukraine, the US, the UK, Italy and Russia (IV) (NCT04163900)
- 16 Sep 2021 Efficacy data form ABC-08 trial in Biliary cancer presented at the 46th European Society for Medical Oncology Congress (ESMO-2021)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Bladder-cancer(Combination therapy, First-line therapy) in United Kingdom (IV)